Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Payables: 2019-2024

Historic Payables for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $1.2 million.

  • Fulcrum Therapeutics' Payables fell 29.32% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 48.89%. This contributed to the annual value of $1.2 million for FY2024, which is 57.78% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Payables stood at $1.2 million for FY2024, which was down 57.78% from $2.8 million recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Payables ranged from a high of $4.8 million in FY2021 and a low of $1.2 million during FY2024.
  • Moreover, its 3-year median value for Payables was $2.8 million (2023), whereas its average is $2.5 million.
  • Its Payables has fluctuated over the past 5 years, first soared by 86.60% in 2020, then plummeted by 57.78% in 2024.
  • Fulcrum Therapeutics' Payables (Yearly) stood at $4.1 million in 2020, then grew by 17.38% to $4.8 million in 2021, then dropped by 24.02% to $3.6 million in 2022, then dropped by 24.22% to $2.8 million in 2023, then crashed by 57.78% to $1.2 million in 2024.